Our progressive strategy of investing in under-ventured geographies and sectors, coupled with our expertise in building deep relationships with entrepreneurs, executives, and investment partners across the healthcare industry, are significant factors contributing to our success.
Venture the Path Less TraveledTM
A healthcare venture capital firm rooted in the Midwest
Life Science Tools
We seek innovations that solve (big) healthcare problems and make a transformational impact from teams who are diverse in thought, geography, and demographics.
We have a proven formula for identifying early-stage startups that can create value in a capital-efficient manner, accelerate portfolio value, and deliver superior returns.
We invest in today’s ideas to forge a path for better healthcare tomorrow
Where NeuMoDx started?
Molecular diagnostics is one of the fastest-growing segments within the in-vitro diagnostics market, but existing systems are expensive, complex, and lack sophisticated automation. Through a unique combination of automation and microfluidics, the NeuMoDx Molecular clinical PCR systems offer best-in-class ease of use, throughput, and cost per test.
Where NeuMoDx is today?
Arboretum collaborated with the team to set the strategic direction that helped accelerate the company’s product development timeline and helped recruit new investors. Since Arboretum’s investment, NeuMoDx gained regulatory approvals for its first assays, launched its product, and in September 2020, QIAGEN acquired NeuMoDx to strengthen its portfolio of automated molecular testing.
We fuel the future of healthcare
Shifting the venture capital paradigm
We are proud to be a Midwest venture capital firm operating with transparency, integrity, and approachability to help you realize your entrepreneurial and investor goals. Together, we’ll positively impact patients, communities, and healthcare.
I’ve worked with many venture capital investors over my career, but Tom Shehab and the team at Arboretum Ventures are more than investors; they're proactive, involved partners. They collaborate with us, leaning in to tackle challenges shoulder to shoulder. Their steady devotion and vast network have been catalysts for our growth in advancing neuromodulation for autoimmune diseases.Heather SimonsenCEO – Boomerang Medical
Dan Kidle and the Arboretum team have exhibited profound dedication to nurturing our company's growth as we seek to revolutionize care for critically ill patients. Their involvement extends beyond just friendly advice; they are integral to our strategic decision-making process, offering invaluable insights, guidance, and connections.Joe EiblCEO – Flosonics Medical
Jan is a leading advocate for innovations in healthcare across our world. Her focus and dedication to enable innovation in medical devices in particular, have had great impacts in human lives across various disease states. At Koya, as we focus on transforming venous and lymphatic care, having Jan not only invest through Arboretum but also provide her counsel, advocacy, and wisdom has greatly enabled our path forward. I am personally grateful for Jan’s support and strength that any founder or CEO would desire.Andy Doraiswamy PhDCEO – Koya Medical
Beyond providing growth capital, Tim Petersen and Arboretum Ventures have quickly become an indispensable partner to Convergent Dental. Their contributions range from Tim’s thoughtful leadership on our board to making their impressive advisory board available to me to gain their insights on a variety of strategic topics. In fact, following a recent presentation to their advisory board, one of the members made himself available for a 1:1 mentoring discussion that materially influenced a recent transaction that are in the process of completing.Rob GershonCEO – Convergent Dental
Paul McCreadie and the Arboretum team bring a solid foundation of investing experience and a deep network of industry partners that have helped shape our development strategy at Allay. I can rely on his consistent support and thoughtful approach to board discussions whether things are going well or if we are facing challenges.Adam GridleyCEO – Allay Therapeutics